Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06077682
Other study ID # Cycloplegic Refraction & ET
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date September 1, 2023
Est. completion date December 1, 2024

Study information

Verified date October 2023
Source Islamic Hospital, Jordan
Contact Hashem Abu Serhan, MBBS
Phone +974-77912335
Email hashemabusarhan@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary outcome of this study is to compare cyclopentolate 1% and tropicamide 1% for cycloplegic refractions in pediatric populations with esotropia. This will be a prospective double-blinded randomized clinical trial (RCT), multi-center, with randomized sequencing of cycloplegic agent; each patient received one agent at one visit, and the other agent in the next visit (2 different visits ≥ 1 week apart) within 3 months.


Description:

Many studies have been conducted over the last few decades to assess the need for cycloplegia in assessing refractive errors. Plenty of research on pediatric populations has demonstrated that a lack of cycloplegia may contribute to an overestimation of myopia prevalence or substantial mistakes in estimating the prevalence of emmetropia and hyperopia. (1,2) The amount of refractive error varies by individual, as well as the type of cycloplegic refractive error. (3) As a result, there is no reliable method for adjusting non-cycloplegic refractions to approximate cycloplegic refractions. Consideration should be given to the type of cycloplegic agent to be used, preferred dosing, optimal methods of instillation, indications for use, and potential side effects. Despite the fact that the benefits of a cycloplegic examination are undeniable, there is still some confusion and various practice methods when it comes to cycloplegic exams. (4) Although atropine is the most potent cycloplegic agent currently available in clinical practice, its long duration of action (up to 12 days) and well-known side effects have shifted clinical practice toward cyclopentolate use. Cyclopentolate has been shown to provide effective cycloplegia, even in patients with moderate to severe hyperopia, with a relatively short duration of action (up to 24 hours) and fewer side effects. Thus, since its introduction in 1951, cyclopentolate has largely replaced atropine as the standard of care for pediatric cycloplegic examination. (4,5,6) Nevertheless, numerous adverse effects of cyclopentolate for children have been observed, including dry mouth and skin, tachycardia, fever, hallucinations, delirium, restlessness, seizures, ataxia, acute midbrain hemorrhage, and even death. (7,8,9) Many studies compared cyclopentolate to tropicamide for cycloplegia. (10, 11, 12) Tropicamide, unlike cyclopentolate, is a cycloplegic with a rapid onset and a short duration of action lasting up to 6 hours. In addition, fewer side effects have been reported when compared to cyclopentolate. (3,11) According to the literature, cyclopentolate may cause +0.175 to +0.39 D more hyperopia than tropicamide, which is clinically insignificant. (10,11,13) Furthermore, it has been discovered that there is a strong correlation between the time spent waiting to complete the exam and patient satisfaction levels, so reducing the waiting time clearly increases satisfaction levels. (14, 15) Esotropia is a convergent misalignment of the visual axes. Esotropia can be categorized in a variety of ways, usually based on age of onset or underlying causes: Infantile esotropia or acquired esotropia or accommodative esotropia, either normal accommodative convergence/accommodation (AC/A) ratio or high AC/A ratio or partially accommodative esotropia or Nonaccommodative esotropia, and Sensory esotropia. (16) Prevalence estimates of strabismus range from 0.8% to 6.8% in different populations. In the United States, esotropia and exotropia have similar prevalence rates, whereas in Ireland esotropia has been reported five times more frequently than exotropia, and in Australia esotropia has been reported to be twice as frequent as exotropia. (17) The prevalence of esotropia in children increases with age (e.g., higher prevalence at 4 to 6 years compared with 6 to 11 months), moderate anisometropia, and moderate amounts of hyperopia. (18) The potential benefits of treatment for esotropia include promoting binocular vision and improving visual function in each eye. (19) If binocularity is achieved, the number of surgical procedures over a lifetime and overall cost to society may be reduced. (20) Fusion and stereopsis are necessary for some careers and may be useful in sports such as baseball and activities such as needlepoint and watching 3D movies. (21) The appearance of crossed eyes may reduce employment opportunities because of stigma and bias. (22) In addition, binocular alignment is important for the development of a positive self-image and enhances social interactions by normalizing appearance as well as eye contact. (23) In one study, children aged 5 years and older expressed a negative feeling about dolls that had been altered to be esotropic or exotropic. (24) In another study, elementary school teachers rated personal characteristics of children with esotropia and exotropia more negatively than orthotropic children. (25) In a sample of children enrolled in the Multi-ethnic Pediatric Eye Disease Study, strabismus was associated with a decreased general health-related quality of life in preschool children, based on the parents' proxy reporting. (26) Adequate cycloplegia is necessary for accurate retinoscopy in children because of their increased accommodative tone compared with adults. The aim of this randomized clinical trial (RCT) is to explore the cycloplegic effect of tropicamide versus cyclopentolate in refracting pediatric subjects with esotropia.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 1, 2024
Est. primary completion date September 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 3 Years to 16 Years
Eligibility Inclusion Criteria: Alignment: subjects with esotropia Age: 3-16 years Brown irides; grade 4 and 5 using iris color classification system developed by Seddon et al Duration: 2 different visits = 1 week apart within 3 months Exclusion Criteria: Abnormal red reflex (e.g., media opacity) History of heart or neurological diseases History of developmental delay History of a previous allergy to cycloplegic agents Presence of syndromes (e.g., Down's syndrome) History of intraocular surgery

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cyclopentolate
Well-known eye drop used for cycloplegic refraction among children.
Tropicamide
Well-known eye drop used for cycloplegic refraction among children.

Locations

Country Name City State
Jordan Yarmouk University Irbid
Qatar Hamad Medical Corporation Doha

Sponsors (3)

Lead Sponsor Collaborator
Islamic Hospital, Jordan Jordan University of Science and Technology, Yarmouk University

Countries where clinical trial is conducted

Jordan,  Qatar, 

Outcome

Type Measure Description Time frame Safety issue
Primary Spherical equivalent (SE) mean difference between cyclopentolate and tropicamide To study the SE of each drug and compare the mean difference between cyclopentolate and tropicamide To study the SE of each drug and compare the mean difference between cyclopentolate and tropicamide To study the SE of each drug and compare the mean difference between cyclopentolate and tropicamide To study the SE of each drug and compare the mean difference between cyclopentolate and tropicamide To study the SE mean difference between cyclopentolate and tropicamide 3 months
Secondary Amplitude of accommodation To measure the depth of cycloplegia mean difference between cyclopentolate and tropicamide 3 months
See also
  Status Clinical Trial Phase
Completed NCT04532099 - Clinical Comparison of Two Daily Wear Frequent Replacement Silicone Hydrogel Soft Contact Lenses N/A
Completed NCT05039112 - Clinical Comparison of 2 Daily Disposable Toric Soft Contact Lenses N/A
Completed NCT03670303 - Trial of an Educational Intervention to Promote Spectacle Use Among Secondary School Children in Islamabad, Pakistan N/A
Completed NCT02255474 - Bifocal Lenses In Nearsighted Kids N/A
Not yet recruiting NCT03222661 - Direct Comparison of SVOne Obtained Refraction to Subjective Manifest Refraction N/A
Completed NCT04055519 - Clinical Performance Assessment of a Daily Wear Monthly Replacement Soft Silicone Hydrogel Contact Lens N/A
Recruiting NCT05049070 - Study to Evaluate the Reliability, Validity and Safety of Subjective Mobile Refraction N/A
Completed NCT04527978 - Clinical Comparison of 2 Daily Disposable Contact Lenses - Pilot Study 1 N/A
Completed NCT01430247 - Vision Screening for the Detection of Amblyopia N/A
Not yet recruiting NCT04077086 - Correcting Myopia Among Secondary School Children to Increase Academic High School Attendance Rates in Rural Communities N/A
Withdrawn NCT04352868 - Customizing Myopia Control With Multifocal Toric Contact Lens N/A
Completed NCT04528017 - Clinical Comparison of 2 Daily Disposable Contact Lenses - Pilot Study 2 N/A
Recruiting NCT04338880 - Academic Performance and Refractive Error
Recruiting NCT04545073 - Outcomes of a Trifocal IOL in Post-refractive Patients
Enrolling by invitation NCT05992675 - Air Optix® Night and Day® Aqua Continuous Wear
Enrolling by invitation NCT05976750 - Air Optix® Night and Day® Aqua Daily Wear
Recruiting NCT04693247 - Handheld Device Compared With a Standard Eye Care Diagnostic Device in Measuring Ophthalmic Refraction N/A
Recruiting NCT06065631 - Seeing to Learn in Sierra Leone N/A
Not yet recruiting NCT05550740 - Repeated Low-Level Red-Light Therapy for Shortening Axial Length N/A
Not yet recruiting NCT06044688 - EyeQue VisionCheck 510(k) Clinical Trial N/A